Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

The dark side of PD-1 receptor inhibition

Nature volume 552, pages 41–42 (2017)Cite this article

Subjects

Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves. See Letter p.121

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Dual roles for the PD-1 receptor protein.

Notes

  1. See all news & views

References

  1. Wartewig, T. et al. Nature 552, 121–125 (2017).

    Article  ADS  CAS  Google Scholar 

  2. Sharpe, A. H. & Pauken, K. E. Nature Rev. Immunol. http://doi.org/gb2z5d (2017).

  3. Navarro, M. N. & Cantrell, D. A. Nature Immunol. 15, 808–814 (2014).

    Article  CAS  Google Scholar 

  4. Wolchok, J. D. et al. N. Engl. J. Med. 377, 1345–1356 (2017).

    Article  CAS  Google Scholar 

  5. Borghaei, H. et al. N. Engl. J. Med. 373, 1627–1639 (2017).

    Article  Google Scholar 

  6. Hude, I., Sasse, S., Engert, A. & Bröckelmann, P. J. Haematologica 102, 30–42 (2017).

    Article  CAS  Google Scholar 

  7. Wei, S. C. et al. Cell 170, 1120–1133 (2017).

    Article  CAS  Google Scholar 

  8. Gordon, S. R. et al. Nature 545, 495–499 (2017).

    Article  ADS  CAS  Google Scholar 

  9. Lesokhin, A. M. et al. J. Clin. Oncol. 34, 2698–2704 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, 02138, Massachusetts, USA

    Aya Ludin & Leonard I. Zon

  2. the Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts

    Leonard I. Zon

  3. the Howard Hughes Medical Institute, Boston

    Leonard I. Zon

Authors
  1. Aya Ludin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonard I. Zon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonard I. Zon.

Related links

Related links

Related links in Nature Research

https://doi.org/10.1038/nature23093

https://doi.org/10.1038/nature17310

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ludin, A., Zon, L. The dark side of PD-1 receptor inhibition. Nature 552, 41–42 (2017). https://doi.org/10.1038/nature24759

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature24759

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer